[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 347
Citations 0
Lab Reports
July 2, 2014

Investigational Drug May Fight Asbestos-Related Cancer

JAMA. 2014;312(1):19. doi:10.1001/jama.2014.7647

Studies using a mouse model and cells from patients with pleural mesothelioma found that an investigational agent appears to slow tumor growth in cancer cells from mesothelioma tumors lacking a tumor suppressor protein called merlin (Shapiro IM et al. Sci Transl Med. 2014;6[237]:237ra68).

Expression of merlin expression is often lost in malignant pleural mesothelioma (MPM), an asbestos-induced aggressive cancer with limited treatment options. This protein is found at cell-cell boundaries, where it plays a role in the maturation of junctions that form attachments between cells. The agent, VS-4718, inhibits focal adhesion kinase (FAK), weakening cells’ adhesion to the extracellular matrix that provides crucial support to the cancer cells.

First Page Preview View Large
First page PDF preview
First page PDF preview